AUTHORS
Kevin Charles Miller, MD, Teng Fei, PhD2, Jennifer Haber3, Minsu Jaun4, Mirae Baichoo, PhD5, Anish Kumar Simhal, PhD6, Saki Clarke7, Francesco Maura, MD8, Kylee Maclachlan, MD, PhD9, Maximilian Merz, MD10, Malin Hultcrantz, MD PhD11, Sham Mailankody, MBBS12, Neha Korde, MD13, Hani Hassoun, MD14, Srideve Rajeeve, MD15, Issam S Hamadeh, Pharm.D.16, Hamza Hashmi, M.D.17, Ross Firestone, MD/PhD18, Eric Matthew Jurgens, MD19, Gunjan L. Shah, MD, MS20, Michael Scordo, MD21, Heather J. Landau, MD22, Sergio Giralt, MD23, Saad Z. Usmani, MD24, Jonathan Peled, MD/PhD25, Urvi A. Shah, MD, MS, DipABLM26, Alexander M. Lesokhin, MD27
AFFILIATIONS
1 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Sloan Kettering Institute, New York, New York, United States
4 Sloan Kettering Institute, New York, New York, United States
5 Sloan Kettering Institute, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Introduction:
Bispecific antibodies (BsAb) targeting BCMA and GPRC5D are increasingly used in the treatment of multiple myeloma (MM). Host immune states affect BsAb responsiveness in MM. The gut microbiota shapes immune function and correlates with response to immunotherapies including immune checkpoint blockade (ICB) and chimeric antigen receptor (CAR) T cell therapies. We hypothesized that gut microbiota features are associated with clinical responses to BsAb therapy in patients with relapsed/refractory MM.
Methods:
Stool samples were prospectively collected from patients immediately before or during step-up dosing of standard-of-care BsAb at our center. Shotgun metagenomic sequencing and 16S rRNA gene amplicon sequencing were performed on all stool samples; metagenomic data were used for primary analyses. Alpha-diversity was calculated using Simpson’s reciprocal index. Between-group compositional differences (beta-diversity) were defined by Bray-Curtis distance and evaluated with PERMANOVA. FLORAL models were used to select predictive microbial taxa (Fei Cell Rep Methods 2024). Amino-acid sequences for Acetyl CoA-pathway butyrate-producing genes were calculated using ShortBRED as reads per kilobase million (RPKM) (Kaminski PLoS Comput Biol 2015). Clinical data were recorded, and responses were assessed per IMWG guidelines. Analyses used R (4.6.1).
Results:
56 patients with relapsed/refractory MM were included: 32 (57%) received BCMA-directed BsAb (teclistamab or elranatamab) and 24 (43%) received GPRC5D-directed BsAb (talquetamab). The median number of prior lines of therapy was 5. These included prior autologous transplant (n=32, 57%), prior CAR T (n=19, 34%), and prior BsAb (n=9, 16%). Median time of fecal sample collection relative to the first step-up dose of BsAb was 2 days (IQR 1-4). Sampling timepoint was not associated with community composition (PERMANOVA F=0.84, P=0.929) or alpha-diversity (linear R2=0.004, P=0.642). Among the cohort, 21/56 patients (38%) were exposed to antibiotics within 30 days prior to fecal sampling. Beta-diversity did not differ by antibiotic exposure, including among the 7/56 (13%) that received antibiotics deemed high-risk for gut microbiota disruption.
Six patients received bridging BsAb prior to CAR T and were excluded from efficacy analyses. The objective response rate among 50 response-evaluable patients was 76%, with n=21 (42%) achieving ≥CR. The 1-year estimated progression-free survival (PFS) was 43.6% (95% confidence interval [CI], 31.9-59.5). Neither alpha-diversity nor beta-diversity distinguished responders from non-responders. Since whole-community metrics are insensitive to potentially relevant microbial differences, we used the FLORAL analysis package to evaluate whether enrichment or depletion of specific taxa was associated with outcomes. With this approach, Phascolarctobacterium faecium predicted both ≥CR response and longer PFS. This was also replicated in the orthogonal 16S dataset for both endpoints at the genus level. P. faecium was present in 23/56 patients (41%); median PFS was 31.3 vs. 3.8 months in patients with and without P. faecium, respectively (log-rank P<0.001). In a multivariable Cox model adjusted for BsAb target, prior CAR T and presence of high-risk cytogenetics, P. faecium remained significantly associated with PFS (hazard ratio 0.20, 95% CI 0.08-0.49, P<0.001). P. faecium has previously been associated with increased responsiveness to ICB (Lee Nat Med 2022) and CAR T (Saha Blood Adv 2025), supporting the biological plausibility of this finding.
Microbiome-derived short-chain fatty acids such as butyrate can also augment immunotherapy responses (Luu Nat Commun 2021), so we examined butyrate-producing taxa. The summed relative abundance of butyrate-producers (per Haak Blood 2018) was 3.1-fold higher in patients achieving ≥CR (median 12.2% vs. 4.0%, Wilcoxon P=0.046). Butyrate-synthesis gene abundance trended toward higher levels in patients achieving ≥CR (median RPKM 373 vs. 208, Wilcoxon P=0.087) suggesting increased butyrate production may be associated with deeper BsAb responses.
Conclusions:
To our knowledge, this is the largest metagenomic evaluation of gut microbiota in patients receiving BsAb therapy in any cancer type. We identified microbial features associated with response, including enrichment of P. faecium and butyrate-producing taxa. These findings support further study of microbiota-targeted interventions to improve BsAb responses in MM.
DISCLOSURES
Kevin Charles Miller, MD: MD Education - Honoraria